Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125026 | 0.85 | SLC2A1 (0.43) | SLC2A1RARBKDM4ELMNATHRA | |
| SCHEMBL864278 | 0.77 | SMN1; SMN2 (0.41) | SLC2A1RARBALDH1A1 | |
| SCHEMBL864065 | 0.76 | THRA (0.59) | RARBLMNAALDH1A1THRA | |
| SCHEMBL864302 | 0.74 | SLC2A1 (0.57) | SLC2A1KDM4EALDH1A1KMT2A | |
| SCHEMBL864133 | 0.74 | SMN1; SMN2 (0.40) | SLC2A1RARBKDM4EALDH1A1 | |
| SCHEMBL864035 | 0.73 | SLC2A1 (0.56) | SLC2A1KDM4EALDH1A1KMT2A | |
| SCHEMBL13236872 | 0.71 | SLC2A1 (0.55) | SLC2A1KDM4EALDH1A1 | |
| SCHEMBL874538 | 0.70 | MEN1 (0.47) | LMNAALDH1A1KMT2A | |
| SCHEMBL10625050 | 0.69 | ALDH1A1 (0.55) | SLC2A1RARBLMNAALDH1A1KMT2A | |
| SCHEMBL6692772 | 0.69 | MMP9 (0.57) | SLC2A1LMNAMMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619184-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2619184-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | The Regents of the University of Michigan (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012040527-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | SLC2A1 4639/4885RARB 2882/4885KDM4E 1053/4885 |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | SLC2A1 4639/4885RARB 2882/4885KDM4E 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.